Charles Schwab’s Infinity Pharmaceuticals, Inc. INFI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-29,948
| Closed | -$16.6K | – | 3604 |
|
|
2022
Q4 | $16.6K | Hold |
29,948
| – | – | ﹤0.01% | 3515 |
|
|
2022
Q3 | $36K | Hold |
29,948
| – | – | ﹤0.01% | 3407 |
|
|
2022
Q2 | $19K | Sell |
29,948
-205,292
| -87% | -$158K | ﹤0.01% | 3525 |
|
|
2022
Q1 | $269K | Buy |
235,240
+19,790
| +9% | +$23.6K | ﹤0.01% | 3242 |
|
|
2021
Q4 | $485K | Hold |
215,450
| – | – | ﹤0.01% | 3153 |
|
|
2021
Q3 | $737K | Sell |
215,450
-122
| -0.1% | -$376 | ﹤0.01% | 2995 |
|
|
2021
Q2 | $645K | Buy |
215,572
+185,624
| +620% | +$587K | ﹤0.01% | 3084 |
|
|
2021
Q1 | $97K | Hold |
29,948
| – | – | ﹤0.01% | 3383 |
|
|
2020
Q4 | $64K | Hold |
29,948
| – | – | ﹤0.01% | 3343 |
|
|
2020
Q3 | $36K | Hold |
29,948
| – | – | ﹤0.01% | 3296 |
|
|
2020
Q2 | $28K | Hold |
29,948
| – | – | ﹤0.01% | 3282 |
|
|
2020
Q1 | $26K | Hold |
29,948
| – | – | ﹤0.01% | 3182 |
|
|
2019
Q4 | $29K | Hold |
29,948
| – | – | ﹤0.01% | 3147 |
|
|
2019
Q3 | $31K | Hold |
29,948
| – | – | ﹤0.01% | 3145 |
|
|
2019
Q2 | $54K | Hold |
29,948
| – | – | ﹤0.01% | 3143 |
|
|
2019
Q1 | $57K | Buy |
+29,948
| New | +$43.8K | ﹤0.01% | 3110 |
|
|
2017
Q2 | – | Sell |
-67,500
| Closed | -$219K | – | 3152 |
|
|
2017
Q1 | $219K | Hold |
67,500
| – | – | ﹤0.01% | 2915 |
|
|
2016
Q4 | $92K | Hold |
67,500
| – | – | ﹤0.01% | 3046 |
|
|
2016
Q3 | $106K | Sell |
67,500
-19,600
| -23% | -$30.1K | ﹤0.01% | 3007 |
|
|
2016
Q2 | $116K | Sell |
87,100
-65,393
| -43% | -$306K | ﹤0.01% | 3042 |
|
|
2016
Q1 | $804K | Buy |
152,493
+1,903
| +1% | +$11.6K | ﹤0.01% | 2412 |
|
|
2015
Q4 | $1.18M | Sell |
150,590
-450,432
| -75% | -$3.88M | ﹤0.01% | 2315 |
|
|
2015
Q3 | $5.08M | Buy |
601,022
+36,365
| +6% | +$335K | 0.01% | 1463 |
|
|
2015
Q2 | $6.18M | Sell |
564,657
-261,553
| -32% | -$3.36M | 0.01% | 1408 |
|
|
2015
Q1 | $11.6M | Buy |
826,210
+448,498
| +119% | +$6.86M | 0.02% | 900 |
|
|
2014
Q4 | $6.38M | Buy |
377,712
+257,123
| +213% | +$3.74M | 0.01% | 1252 |
|
|
2014
Q3 | $1.62M | Sell |
120,589
-4,893
| -4% | -$58.3K | ﹤0.01% | 2079 |
|
|
2014
Q2 | $1.6M | Sell |
125,482
-784
| -0.6% | -$8.17K | ﹤0.01% | 2096 |
|
|
2014
Q1 | $1.5M | Sell |
126,266
-6,495
| -5% | -$87.2K | ﹤0.01% | 2083 |
|
|
2013
Q4 | $1.83M | Buy |
132,761
+12,597
| +10% | +$178K | ﹤0.01% | 1967 |
|
|
2013
Q3 | $2.05M | Buy |
120,164
+17,919
| +18% | +$343K | ﹤0.01% | 1826 |
|
|
2013
Q2 | $1.7M | Buy |
+102,245
| New | +$3.16M | ﹤0.01% | 1855 |
|
Other funds holding INFI
BI
SFM
CC
E
Charles Schwab's INFI Position: Q1 2023 in Review
Charles Schwab sold out of Infinity Pharmaceuticals, Inc. (INFI) in Q1 2023, closing a stake of 29,948 shares — an estimated $16.6K sold.
Charles Schwab first reported a position in INFI in Q2 2013 and held it in 32 quarters. The position peaked at $11.6M in Q1 2015. 53 funds tracked by Wall St. Rank hold INFI as of Q1 2023.
- Charles Schwab reported no remaining Infinity Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
- Charles Schwab sold 29,948 Infinity Pharmaceuticals, Inc. shares in Q1 2023, an estimated $16.6K.
- Charles Schwab first reported a position in Infinity Pharmaceuticals, Inc. in Q2 2013 and held it in 32 quarters.
- Charles Schwab's Infinity Pharmaceuticals, Inc. position peaked at $11.6M in Q1 2015.
- 53 funds tracked by Wall St. Rank held Infinity Pharmaceuticals, Inc. as of Q1 2023.
Based on Charles Schwab's 13F filing for Q1 2023, filed 12 May 2023.